Both in Pharmaceuticals
Perspective Therapeutics vs PDS Biotechnology
Over the past year CATX returned −62.7% and PDSB returned +46.3%; their daily moves had a correlation of 0.01.
CATX −62.7% PDSB +46.3%Growth of $1, one year, split-adjusted
| Metric | CATX | PDSB |
|---|---|---|
| Price | $0.8702 | $1.30 |
| Market cap | $99.3M | $94.2M |
| Today | −1.11% | −7.80% |
| 1 month | −63.1% | +24.4% |
| 6 months | −77.2% | +22.6% |
| Year to date | −68.4% | +68.9% |
| 1 year | −66.5% | +39.2% |
| Revenue growth (YoY) | −72.1% | — |
| Gross margin | 100.0% | — |
| Net margin | −33069.1% | — |
| P/E (TTM) | — | — |
| Price / sales | 242.9× | — |
| Net cash | $235.3M | $1.2M |
| Dividend yield | — | — |
| Volatility (60d) | 117.1% | 228.8% |
| Short % of float | 17.1% | 8.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).